Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma
Raju Kandimalla(Baylor University Medical Center), Ajay Goel(City of Hope), Saurav Mallik(Harvard University), Susan Tsai(The Ohio State University Wexner Medical Center), Song Cheol Kim(Ulsan College), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), Daniel D. Von Hoff(Translational Genomics Research Institute), Xi Chen(University of Miami), Hideo Baba(Kaketsuken (Japan)), Fuminori Sonohara(Nagoya University), Tadanobu Shimura(Mie University), Yasuhiro Kodera(Nagoya Medical Center)
Cited by 20
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
|Gastroenterology|2015|814
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Pathways of Colorectal Carcinogenesis
|Gastroenterology|2019|594